logo-loader

Botanix Pharmaceuticals to commence acne treatment patient study

Published: 08:50 22 Aug 2017 AEST

shutterstock_114430699
The study is scheduled to be completed before the end of 2017

Botanix Pharmaceuticals (ASX:BOT) has received the Human Research Ethics Committee approval to proceed further with the patient study for its lead acne treatment product, BTX 1503.

BTX 1503 is a topical treatment for moderate to severe acne, which utilises synthetic cannabidiol as the active ingredient, together with Botanix’s proprietary Permetrex™ drug delivery technology.

The delivery performance of Permetrex™ allows targeting of the relevant organs in the skin, while avoiding excess drug being deposited directly into the blood stream.

The ethics approval pushes the phase 1b acne patient clinical study at several leading dermatology clinics in Australia.

Botanix’s phase 1b study is scheduled to be completed before the end of the 2017 calendar year.

The planned acne patient study will be the first anywhere in the world to utilise synthetic cannabidiol as the active drug for the treatment of skin disease.

BTX 1503 is targeting the prescription acne market that currently generates more than US$4.5 billion in annual sales.

In addition, the company has BTX 1204 in the pipeline, which is an atopic dermatitis treatment product and BTX 1701, a product that removes excess oil from the skin for the treatment of acne.

Botanix completed a $7.4 million capital raising in April via a significantly oversubscribed share placement to new and existing shareholders.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

2 hours, 11 minutes ago